Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Hold” from Analysts

Shares of Sanofi (NASDAQ:SNY) have been assigned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $51.00.

A number of brokerages have recently issued reports on SNY. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Monday, April 20th.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $44.25 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The business’s 50 day moving average price is $45.14 and its 200-day moving average price is $46.55. The firm has a market capitalization of $107.28 billion, a PE ratio of 12.36, a P/E/G ratio of 1.09 and a beta of 0.34. Sanofi has a 1 year low of $42.28 and a 1 year high of $52.68.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were paid a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. This represents a dividend yield of 559.0%. Sanofi’s dividend payout ratio is 49.16%.

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the stock. CSM Advisors LLC purchased a new stake in Sanofi in the third quarter valued at $18,244,000. Caprock Group LLC purchased a new stake in shares of Sanofi in the 3rd quarter valued at $1,347,000. Natixis Advisors LLC raised its holdings in shares of Sanofi by 11.8% in the 3rd quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock valued at $146,952,000 after buying an additional 327,569 shares during the period. Assetmark Inc. raised its holdings in shares of Sanofi by 25.0% in the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after buying an additional 71,356 shares during the period. Finally, XY Capital Ltd purchased a new stake in shares of Sanofi in the 3rd quarter valued at $1,603,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.